These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 7575681)

  • 1. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
    Mülder HS; Dekker H; Pinedo HM; Lankelma J
    Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
    Mankhetkorn S; Teodori E; Garnier-Suillerot A
    Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
    Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
    Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturable P-glycoprotein kinetics assayed by fluorescence studies of drug efflux from suspended human KB8-5 cells.
    Ghauharali RI; Westerhoff HV; Dekker H; Lankelma J
    Biochim Biophys Acta; 1996 Jan; 1278(2):213-22. PubMed ID: 8593279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
    Toffoli G; Simone F; Gigante M; Boiocchi M
    Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
    Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
    Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efflux of anthracyclines in multidrug-resistant cell lines.
    Coley HM; Twentyman PR; Workman P
    Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
    Hargrave RM; Davey MW; Davey RA; Kidman AD
    Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
    Mankhetkorn S; Garnier-Suillerot A
    Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine.
    Frézard F; Pereira-Maia E; Quidu P; Priebe W; Garnier-Suillerot A
    Eur J Biochem; 2001 Mar; 268(6):1561-7. PubMed ID: 11248673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.
    Kang W; Weiss M
    Pharm Res; 2001 Nov; 18(11):1535-41. PubMed ID: 11758760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells.
    Wielinga PR; Westerhoff HV; Lankelma J
    Eur J Biochem; 2000 Feb; 267(3):649-57. PubMed ID: 10651800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
    Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
    Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
    Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
    Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells.
    Lautier D; Bailly JD; Demur C; Herbert JM; Bousquet C; Laurent G
    Int J Cancer; 1997 Apr; 71(2):292-9. PubMed ID: 9139856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
    Friche E; Demant EJ; Sehested M; Nissen NI
    Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
    Pereira E; Tarasiuk J; Garnier-Suillerot A
    Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.
    Michieli M; Michelutti A; Damiani D; Pipan C; Raspadori D; Lauria F; Baccarani M
    Leuk Lymphoma; 1993 Feb; 9(3):255-64. PubMed ID: 8097129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance-modifying components in human plasma with potential clinical significance.
    Mülder HS; Pinedo HM; Timmer AT; Rao BR; Lankelma J
    J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.